METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS

• US 20090269315A1
• Filed: 03/30/2009
• Published: 10/29/2009
• Est. Priority Date: 12/07/2001
• Status: Abandoned Application

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Lorem Vascular Pte. Ltd.
• Inventors: Wulur, Isabella, Daniels, Eric, Strem, Brian M., Fraser, John K., Hedrick, Marc H., Zhu, Min
• Application Number:
  US12/414,582
• Publication Number:
  US 20090269315A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 Vascular Endothelial cells

Abstract

Cells present in processed lipoaspirate tissue are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.

Claims

1. A method for restoring blood flow in an subject that is identified as having an ischemic condition, comprising:

administering to the subject an amount of a composition comprising a concentrated cell population that comprises adipose derived stem cells effective to restore blood flow to the ischemic region of said subject.

2. The method of claim 1, wherein said composition comprising said concentrated cell population that comprises adipose-derived stem cells further comprises adipose-derived progenitor cells.

3. The method of claim 1, wherein said ischemic condition is congestive heart failure.

4. The method of claim 1, wherein said ischemic condition is myocardial infarction.

5. The method of claim 1, further comprising culturing said concentrated cell population that comprises adipose derived stem cells prior to administration to the patient.

6. The method of claim 1, wherein said concentrated cell population that comprises adipose derived stem cells are grown in culture conditions that promote differentiation towards a myocytic phenotype.

7. The method of claim 6, wherein the cell culture is performed on a scaffold material to generate a two or three dimensional construct configured for placement on or within the heart.

8. The method of claim 7, wherein the scaffold material is resorbable in vivo.

9. The method of claim 1, further comprising modifying said concentrated cell population that comprises adipose-derived stem cells by gene transfer such that expression of one or more genes in the modified adipose derived cells is altered.

10. The method of claim 9, wherein the modification alters the level of angiogenesis in the subject.

11. The method of claim 9, wherein the modification alters the level of arteriogenesis in the subject.

12. The method of claim 9, wherein the modification alters the level of apoptosis in the subject.

13. The method of claim 12, wherein apoptosis of cardiac myocytes is altered.

14. The method of claim 9, wherein the modification results in alteration of the homing properties of the concentrated population of cells comprising adipose derived stem cells.

15. The method of claim 1, wherein said restoring blood flow comprises angiogeneis.

16. The method of claim 1, wherein said restoring blood flow comprises arteriogenesis.

17. The method of claim 1, wherein said restoring blood flow comprises an inhibition of apoptosis.

18. The method of claim 1, wherein said restoring blood flow comprises an inhibition of scar formation.